Clinical Trial News and Research

RSS

Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

In association with its 50th anniversary, the American Society of Clinical Oncology has named Dr. Daniel D. Von Hoff one of ASCO's 50 Oncology Luminaries, celebrating 50 doctors who over the past half-century have significantly advanced cancer care.

9 Mar 2014

FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma

Researchers at the University of California, San Diego School of Medicine have discovered that FDA-approved anti-psychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma. The finding was published in this week's online edition of Oncotarget.

8 Mar 2014

Longtime allies team up to create Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

Three longtime allies have joined forces to create the new Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence.

7 Mar 2014

National clinical trial to test new avenue for tinnitus treatment

UT Southwestern Medical Center will take part in a national clinical trial to test a device that could provide relief for people suffering from tinnitus, a persistent buzzing or ringing sound in the ears. The device uses nervous system stimuli to rewire parts of the brain, in hopes of significantly reducing or removing tinnitus.

7 Mar 2014

Columbia Laboratories repurchases Actavis' block of shares at advantageous price

Columbia Laboratories, Inc. announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014.

7 Mar 2014

New method of protecting women from transmission of HIV is safe

Findings of an early phase clinical trial at the University of Alabama at Birmingham suggest that a possible new method of protecting women from the transmission of HIV is safe.

7 Mar 2014

Cataract surgery followed by use of contact lenses may be better solution for infants

For adults and children who undergo cataract surgery, implantation of an artificial lens is the standard of care. But a clinical trial suggests that for most infants, surgery followed by the use of contact lenses for several years—and an eventual lens implant—may be the better solution.

7 Mar 2014

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Today Boehringer Ingelheim announced results from STARTVerso4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg faldaprevir dose groups.

6 Mar 2014

Tetraphase Pharmaceuticals reports net loss of $11.3 million for Q4 2013

Tetraphase Pharmaceuticals, Inc. today reported financial results for the quarter and full year ended December 31, 2013.

6 Mar 2014

ASTRO white paper recommends specific guidance to follow in the delivery of HDR brachytherapy

The American Society for Radiation Oncology has issued a new white paper, "A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy," that recommends specific guidance to follow in the delivery of high-dose-rate (HDR) brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology, the official clinical practice journal of ASTRO.

6 Mar 2014

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Chronic hepatitis C virus (HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so viral clearance and prevention of relapse are important treatment goals.

6 Mar 2014

Research shows how patient experiences can be used to improve healthcare

A research project led by Oxford University is showing how patient experiences can be used to improve healthcare - not through targets and surveys, but by getting doctors, nurses and patients talking together about care on the ward.

6 Mar 2014

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.

5 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a Phase 2/3 clinical trial of Glassia®, the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat newly diagnosed pediatric patients with type 1 diabetes (T1D).

5 Mar 2014

Curie-Cancer, DNA Therapeutics renew partnership to identify new class of cancer drugs

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and DNA Therapeutics, a biopharmaceutical company that is developing a new class of cancer drugs, are renewing their partnership.

5 Mar 2014

POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Eisai Co., Ltd. and Biogen Idec announced today that they have entered into a collaboration to develop and commercialize two of Eisai's clinical candidates for Alzheimer's disease (AD), E2609 and BAN2401.

5 Mar 2014

Experimental drug nivolumab shrinks tumors in patients with advanced melanoma

An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments.

4 Mar 2014

AAA gets orphan drug designation status for radiopharmaceutical, Gallium-68 DOTATATE

Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM), announced today that they have received orphan drug designation status for their radiopharmaceutical, Gallium-68 DOTATATE.

4 Mar 2014

Clinical Trial News and Research

Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma

Longtime allies team up to create Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

National clinical trial to test new avenue for tinnitus treatment

Columbia Laboratories repurchases Actavis' block of shares at advantageous price

New method of protecting women from transmission of HIV is safe

Cataract surgery followed by use of contact lenses may be better solution for infants

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Tetraphase Pharmaceuticals reports net loss of $11.3 million for Q4 2013

ASTRO white paper recommends specific guidance to follow in the delivery of HDR brachytherapy

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Research shows how patient experiences can be used to improve healthcare

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Curie-Cancer, DNA Therapeutics renew partnership to identify new class of cancer drugs

POZEN reports total revenue of $4.7 million for fourth quarter 2013

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Experimental drug nivolumab shrinks tumors in patients with advanced melanoma

AAA gets orphan drug designation status for radiopharmaceutical, Gallium-68 DOTATATE

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer